TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31583910

Group type: EXPERIMENTAL
Intervention: Right frontal low frequency transcranial magnetic stimulation (TMS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pretreatment EEG (quantitative EEG - qEEG)
Number of subjects: 50
Study: 30639581

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection
Number of subjects: 50
Study: 27966572

Group type: EXPERIMENTAL
Intervention: Traditional Mexican diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: US diet
Number of subjects: 53
Study: 25588169

Group type: EXPERIMENTAL
Intervention: Intraoral digitization (ID)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Extraoral digitization (ED)
Number of subjects: 10
Study: 24161420

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) - 37.5 Gy in 3.75 Gy per fraction delivered twice daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) - 48 Gy delivered in daily fractions of 2 Gy, with or without additional 10 Gy to the tumor bed
Number of subjects: 102
Study: 21371681

Group type: COMPARATOR
Intervention: Naproxcinod 750 mg
Number of subjects: 2734

Group type: COMPARATOR
Intervention: Naproxen 500 mg
Number of subjects: 2734
Study: 19265544

Group type: EXPERIMENTAL
Intervention: Citrate dialysate (C)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Citrate dialysate with calcium supplementation (C+)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acetate dialysate (A)
Number of subjects: 25
Study: 17822973

Group type: EXPERIMENTAL
Intervention: 1-piece AcrySof IOL
Number of subjects: 52

Group type: COMPARATOR
Intervention: 3-piece AcrySof IOL
Number of subjects: 52
Study: 15173725

Group type: EXPERIMENTAL
Intervention: Polyamid filter with conventional ultrafiltration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Polyamid filter with modified ultrafiltration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Polysulfon filter with conventional ultrafiltration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Polysulfon filter with modified ultrafiltration
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 41

Group type: COMPARATOR
Intervention: Modified ultrafiltration
Number of subjects: 41
Study: 11741526

Group type: EXPERIMENTAL
Intervention: Treatment (specific treatment not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimate equation (GEE) technique
Number of subjects: 0
Study: 9505912

Group type: EXPERIMENTAL
Intervention: Abciximab added to intravenous heparin and aspirin regimen
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Cost effectiveness analysis
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Modelled analysis
Number of subjects: 2099
Study: 7977669

Group type: EXPERIMENTAL
Intervention: Home visitation services
Number of subjects: 0
Study: 2543246

Group type: EXPERIMENTAL
Intervention: Max‐EPA (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 17
Study: 4969551

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.d.s.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Verapamil 40 mg t.d.s.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol 100 mg t.d.s.
Number of subjects: 16
Study: 30789855

Group type: EXPERIMENTAL
Intervention: Antioxidants (AO)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 107
Study: 30020812

Group type: EXPERIMENTAL
Intervention: Curcumin 1gr/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phospholipidated curcumin 1gr/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28489804

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 46

Group type: COMPARATOR
Intervention: Aura-i
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both LMAs
Number of subjects: 46
Study: 25605841

Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Rituximab re-treatment (RR)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Both MR and RR
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Avoidant coping style
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Active coping style
Number of subjects: 253
Study: 22921446

Group type: EXPERIMENTAL
Intervention: Envelope flap technique
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Modified triangular flap technique
Number of subjects: 80
Study: 21995679

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (n = 158)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Conventional moxibustion (n = 158)
Number of subjects: 316
Study: 18496812

Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet (n = 7; 25% energy from protein and 45% from carbohydrates)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High glycemic load (HGL) diet (n = 5; 15% energy from protein, 55% energy from carbohydrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High glycemic load (HGL) diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet
Number of subjects: 12
Study: 15083498

Group type: EXPERIMENTAL
Intervention: Aceclofar (Julphar, UAE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bristaflam (Bristol Myers Squibb, Egypt)
Number of subjects: 24
Study: 11594896

Group type: EXPERIMENTAL
Intervention: Integrated care model (n = 285)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Independent care model (n = 307)
Number of subjects: 592
Study: 9852408

Group type: EXPERIMENTAL
Intervention: Solcotrans
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Orth‐Evac
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Redon drainage
Number of subjects: 28

Group type: COMPARATOR
Intervention: Venous blood
Number of subjects: 28
Study: 8271292

Group type: EXPERIMENTAL
Intervention: Fenretinide 200 mg daily for a median of 32 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no fenretinide)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 65
Study: 2929705

Group type: EXPERIMENTAL
Intervention: Artificial tear formulation (solution 15 with demulcent and buffering system, osmolarity 162 mOsm/l)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hypotears (control)
Number of subjects: 11
Study: 29877679

Group type: EXPERIMENTAL
Intervention: Traditional Training Periodization (TTP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Reverse Training Periodization (RTP)
Number of subjects: 17
Study: 27776763

Group type: EXPERIMENTAL
Intervention: Stimulation of SI14 (upper trapezius muscle)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Stimulation of SI8 (distant from the UT muscle)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham group (R3)
Number of subjects: 38
Study: 24849105

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with paclitaxel-eluting first-generation stent
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1095

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1095
Study: 22037137

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 24
Study: 20367667

Group type: EXPERIMENTAL
Intervention: 24 mg/mL hyaluronic acid with pre-incorporated 0.3% lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Equivalent product without lidocaine
Number of subjects: 60
Study: 18397977

Group type: EXPERIMENTAL
Intervention: 6-month thyroid hormone substitution regimen to obtain euthyroidism
Number of subjects: 25

Group type: COMPARATOR
Intervention: Subclinical hyperthyroidism
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patients with hyperthyroidism
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism patients
Number of subjects: 25
Study: 16099293

Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy (60 Gy conventional irradiation delivered over 6 weeks)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation group
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Wait-and-see group
Number of subjects: 1005
Study: 11374333

Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9803985

Group type: EXPERIMENTAL
Intervention: Single oral tablet dose of 20 mg temocapril hydrochloride
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Seven once daily oral tablet doses of 20 mg temocapril hydrochloride
Number of subjects: 36
Study: 8056004

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 2973597

Group type: EXPERIMENTAL
Intervention: Ceftazidime-vancomycin (group A)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ticarcillin-vancomycin-amikacin (group B)
Number of subjects: 66
Study: 31315733

Group type: EXPERIMENTAL
Intervention: NTI-guided sedation assessment
Number of subjects: 87

Group type: COMPARATOR
Intervention: RASS-guided sedation assessment
Number of subjects: 87
Study: 28991614

Group type: EXPERIMENTAL
Intervention: In-the-bag IOL with anterior vitrectomy (Group 1)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Optic capture of IOL without anterior vitrectomy (Group 2)
Number of subjects: 61
Study: 25490706

Group type: COMPARATOR
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 3255

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg + Fluticasone furoate (FF) 50 μg
Number of subjects: 3255

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg + Fluticasone furoate (FF) 100 μg
Number of subjects: 3255

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg + Fluticasone furoate (FF) 200 μg
Number of subjects: 3255
Study: 23337228

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enalapril class 1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo class 1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo/enalapril class 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Placebo/enalapril class 2
Number of subjects: 100
Study: 20352312

Group type: EXPERIMENTAL
Intervention: MEMSCIS program with emergency information forms (EIF)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: MEMSCIS program
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no MEMSCIS program)
Number of subjects: 170
Study: 19846281

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16982058

Group type: EXPERIMENTAL
Intervention: BM‐MNC sorted on a blood cell separator
Number of subjects: 12

Group type: COMPARATOR
Intervention: BM‐MNC isolated by density gradient on Ficoll‐Hypaque
Number of subjects: 12
Study: 15016255

Group type: EXPERIMENTAL
Intervention: Written information provided prior to treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control condition (no written information)
Number of subjects: 56
Study: 11256458

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 9020437

Group type: EXPERIMENTAL
Intervention: Patellectomy with advancement of the vastus medialis obliquus (group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Simple patellectomy (group A)
Number of subjects: 28
Study: 7932194

Group type: EXPERIMENTAL
Intervention: 20 mg/day lovastatin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg/day lovastatin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 80 mg/day lovastatin
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0 mg/day lovastatin (baseline)
Number of subjects: 9
Study: 31980416

Group type: EXPERIMENTAL
Intervention: Dual-Axis Rotational Coronary Angiography (DARCA)
Number of subjects: 503
Study: 29369893

Group type: EXPERIMENTAL
Intervention: Passive insulation
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 292

Group type: COMPARATOR
Intervention: Ambient temperature (19°, 21°, or 23°C)
Number of subjects: 292
Study: 27175685

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg/kg/hour continuous infusion)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50
Study: 24662296

Group type: EXPERIMENTAL
Intervention: Ready-to-use complementary food (RUF)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Whole milk powder
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both interventions (RUF and milk powder)
Number of subjects: 248
Study: 23206453

Group type: EXPERIMENTAL
Intervention: Di Huang Yin Zi (DHYZ)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20187094

Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiation with 4x150 mg/m(2) cisplatin administered in the tumor-feeding artery on Days 1, 8, 15, 22, followed by sodium thiosulfate and 70 Gy in 35 daily fractions.
Number of subjects: 239

Group type: COMPARATOR
Intervention: Intravenous chemoradiation with 3x100 mg/m(2) cisplatin infusion on Days 1, 22, 43 and 70 Gy in 35 daily fractions.
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiation
Number of subjects: 239

Group type: COMPARATOR
Intervention: Intravenous chemoradiation
Number of subjects: 239
Study: 18156614

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 1181
Study: 17042146

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Albuterol 180 microg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 14616279

Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation (ES) of the pelvic floor
Number of subjects: 35

Group type: COMPARATOR
Intervention: Kegel exercise (KE) program
Number of subjects: 35
Study: 11042755

Group type: EXPERIMENTAL
Intervention: Comprehensive care (n = 446)
Number of subjects: 887

Group type: COMPARATOR
Intervention: Routine care (n = 441)
Number of subjects: 887
Study: 8970752

Group type: EXPERIMENTAL
Intervention: 25-point I-GERQ GERD score based on 11 items on the questionnaire
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 25-point I-GERQ GERD score
Number of subjects: 135

Group type: COMPARATOR
Intervention: Normal infants
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Environmental smoke exposure
Number of subjects: 135
Study: 1433121

Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intensity exercise
Number of subjects: 0
Study: 3919531

Group type: EXPERIMENTAL
Intervention: Insulin plus glibenclamide, 5 mg twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 13
Study: 31174713

Group type: EXPERIMENTAL
Intervention: Open-label injectable hydromorphone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Double-blind injectable opioid agonist treatment (iOAT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Open-label injectable hydromorphone vs Double-blind iOAT
Number of subjects: 108

Group type: COMPARATOR
Intervention: Open-label injectable hydromorphone and Double-blind iOAT
Number of subjects: 108
Study: 29947355

Group type: EXPERIMENTAL
Intervention: Virtual reality goggles
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 97
Study: 26884557

Group type: EXPERIMENTAL
Intervention: CGA arm (treatment allocation based on Comprehensive Geriatric Assessment)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Standard arm (chemotherapy allocation based on performance status and age)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: CGA arm
Number of subjects: 494

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 494
Study: 25182272

Group type: EXPERIMENTAL
Intervention: Topical repellents
Number of subjects: 940

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 940
Study: 22268183

Group type: EXPERIMENTAL
Intervention: i.v. iohexol
Number of subjects: 389

Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 389

Group type: COMPARATOR
Intervention: Comparison of iohexol and iopamidol
Number of subjects: 389

Group type: COMPARATOR
Intervention: Contrast-induced nephropathy rates
Number of subjects: 389
Study: 19625343

Group type: EXPERIMENTAL
Intervention: Irinotecan (70 mg/m²) and Docetaxel (25 mg/m²) administered on days 1 and 8 of each 3-week cycle
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Irinotecan and Docetaxel
Number of subjects: 70
Study: 18172223

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day
Number of subjects: 90
Study: 16353468

Group type: EXPERIMENTAL
Intervention: Centric occlusion stabilization oral appliance
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-appliance wearing days
Number of subjects: 22
Study: 11927703

Group type: EXPERIMENTAL
Intervention: Terbinafine for 1 week
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Terbinafine for 2 weeks
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Terbinafine for 4 weeks
Number of subjects: 176
Study: 9809926

Group type: EXPERIMENTAL
Intervention: Carvedilol (10 mg twice a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Arotinolol (10 mg twice a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8561267

Group type: EXPERIMENTAL
Intervention: Oral artesunate (total dose = 550 mg or 9.6 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (total dose = 8.8 mg/kg)
Number of subjects: 50
Study: 2692838

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (LA.P), 160 mg once-daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 322152

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (2 and 10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 31843246

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings for 3 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (no elastic compression)
Number of subjects: 135
Study: 31145281

Group type: EXPERIMENTAL
Intervention: 4 SMS per week offering advice, motivation, and information about medication adherence, physical activity, dietary measures, and smoking cessation (if appropriate)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 4 SMS per week
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 160
Study: 27008585

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (cycle ergometer at 60% HR max for 40 minutes)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 upper and 3 lower extremity movements at 60% of 1-RM, 60 minutes)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Concurrent exercise (combination of aerobic and resistance protocols, 60 minutes)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maximal shuttle run test (4 trials of 40-meter MSRT, 30 minutes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 50
Study: 26480549

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) assisted with surface electromyography (sEMG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional electro-acupuncture (EA)
Number of subjects: 60
Study: 23637279

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchange mask (HME)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo mask (PL)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No mask (NM)
Number of subjects: 53
Study: 21288211

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg pre-incision
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg pre-incision
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg post-incision
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg post-incision
Number of subjects: 175

Group type: COMPARATOR
Intervention: Gabapentin 600 mg pre-incision
Number of subjects: 175

Group type: COMPARATOR
Intervention: Gabapentin 600 mg post-incision
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 18626764

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (15 sessions)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 467
Study: 16424410

Group type: EXPERIMENTAL
Intervention: Formoterol, 24 microg bid
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg bid plus on-demand
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg bid
Number of subjects: 2085

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: All formoterol treatment regimens
Number of subjects: 2085
Study: 12819323

Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Recommended anti-hypertensive therapy
Number of subjects: 650
Study: 10858404

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 79
Study: 9168080

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All patients (CABG)
Number of subjects: 100
Study: 8247239

Group type: EXPERIMENTAL
Intervention: Dexamethasone in high but rapidly decreasing doses
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 43